-
Mashup Score: 5Body Composition in Anti-Obesity Medication Trials - 17 day(s) ago
This Viewpoint contends that focusing only on weight loss as the primary weight medication end point is an inaccurate measure of medication efficacy for both patients and clinicians.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 7GLP-1RAs associated with increased residual gastric content, despite preprocedural fasting - 20 day(s) ago
Once-weekly glucagon-like peptide-1 receptor agonist use was associated with a “significantly higher prevalence” of increased residual gastric content among fasted patients undergoing elective procedures under anesthesia, research showed. “Despite their increasing use, the safety of GLP-1RAs in the perioperative period remains uncertain,” Sudipta Sen, MD, associate
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
🚨NEW🚨 from @JAMASurgery: Once-weekly #GLP1RA 💊 use was associated with a “significantly higher prevalence” of increased residual gastric content among fasted patients undergoing elective procedures under anesthesia 💉. Learn more ⬇️ https://t.co/s3agCYlCl3
-
-
Mashup Score: 7GLP-1RAs associated with increased residual gastric content, despite preprocedural fasting - 23 day(s) ago
Once-weekly glucagon-like peptide-1 receptor agonist use was associated with a “significantly higher prevalence” of increased residual gastric content among fasted patients undergoing elective procedures under anesthesia, research showed. “Despite their increasing use, the safety of GLP-1RAs in the perioperative period remains uncertain,” Sudipta Sen, MD, associate
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
🚨NEW🚨 from @JAMASurgery: Once-weekly #GLP1RA 💊 use was associated with a “significantly higher prevalence” of increased residual gastric content among fasted patients undergoing elective procedures under anesthesia 💉. Learn more ⬇️ https://t.co/s3agCYlCl3
-
-
Mashup Score: 7GLP-1RAs associated with increased residual gastric content, despite preprocedural fasting - 24 day(s) ago
Once-weekly glucagon-like peptide-1 receptor agonist use was associated with a “significantly higher prevalence” of increased residual gastric content among fasted patients undergoing elective procedures under anesthesia, research showed. “Despite their increasing use, the safety of GLP-1RAs in the perioperative period remains uncertain,” Sudipta Sen, MD, associate
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
🚨NEW🚨 from @JAMASurgery: Once-weekly #GLP1RA 💊 use was associated with a “significantly higher prevalence” of increased residual gastric content among fasted patients undergoing elective procedures under anesthesia 💉. Learn more ⬇️ https://t.co/s3agCYlCl3
-
-
Mashup Score: 0News Details - 6 month(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
Unstoppable #GLP1RA semaglutide ‼️ #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis. More protection for our patients. https://t.co/qGtV75oaxZ https://t.co/d6mFOIwnwf
-
-
Mashup Score: 38What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives - 6 month(s) ago
Patients with Type 2 diabetes (T2D) make up about one-quarter to one-third of acute coronary syndrome (ACS) patients. Among patients presenting with ACS, those
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: What about #GLP1RA for all? Recent data and perspectives.https://t.co/4DhpLf14kp A little bit provocative but it may b…
-
-
Mashup Score: 144News Details - 6 month(s) ago
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
2023, the year the #GLP1RA semaglutide can’t lose! #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis Massive news, results in Q1 2024 https://t.co/NIwf8km7Oy https://t.co/deCTcdbxpe
-
A remarkable transformation of care for people with diabetes and kidney disease in less than a decade. Before? Limited to only to RAS blockade. Now? Combination therapy with: - RASi - SGLT2i - GLP-1 RA - ns-MRA 4 pillars of care for diabetes & CKD https://t.co/zHoEs9vx4E https://t.co/kFkcHHcUoy
-
-
Mashup Score: 1
OBJECTIVE. To evaluate the comparative cardiovascular effectiveness and safety of sodium–glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1
Source: diabetesjournals.orgCategories: Cardiologists, Latest HeadlinesTweet-
Comparative Cardiovascular Effectiveness and Safety of #SGLT2i #GLP1RA #DPP4i According to Frailty in T2D https://t.co/D6VrDmMhmd
-
-
Mashup Score: 2
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3-year follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not o …
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiologists, Latest HeadlinesTweet-
Comparing benefits from #SGLT2i and #GLP1RA in #T2D : a #MA https://t.co/oalIaXGYxi
-
-
Mashup Score: 9What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives - 7 month(s) ago
Patients with Type 2 diabetes (T2D) make up about one-quarter to one-third of acute coronary syndrome (ACS) patients. Among patients presenting with ACS, those
Source: academic.oup.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SABOURETCardio: What about #GLP1RA for all? Recent data and perspectives.https://t.co/4DhpLf14kp A little bit provocative but it may b…
-
Great op-ed by @askdrfatima and colleagues. https://t.co/9Emk8Gc60j 🫀@MGH_CLP we work on a lifestyle-first approach with diet and cardio/resistance work augmented with #GLP1RA therapy to preserve lean mass. 💪🏽 Pts get body composition pre and post 🏋🏽♂️ @DishinDietitian